The ESMO Colloquia are innovative sessions within the congress programme that bring together top experts to discuss evolving areas of interest to the oncology community.
The Colloquia are organised by ESMO and supported by the industry in a unique collaboration making them the perfect complement to the scientific and education programme of the Congress.
Targeting RET in lung cancer: State of the art in testing and therapeutics
Saturday, 27 March 2021, 10:30 – 11:50 CET (Central European Time)
View the ESMO Colloquium details
This educational activity is provided by ESMO and co-supported by Lilly Oncology and Thermo Fisher Scientific.
- To inform oncologists on testing modalities for RET molecular aberrations in lung cancer, their characteristics and rationale for assaying biological material.
- To provide an up-to-date review of the effectiveness and feasibility of therapeutics targeting RET in patients with advanced lung cancer.
- To provide a critical analysis of management strategies with RET-targeting agents by applying the ESMO Guidelines and the MCBS and ESCAT tools, in the context of two clinical cases.